Inducción con anticuerpos antilinfocitarios y minimización de esteroides en trasplante renal
Mostra el registre complet Registre parcial de l'ítem
- dc.contributor.author Naesens, Maartenca
- dc.contributor.author Berger, Stefanca
- dc.contributor.author Biancone, Luigica
- dc.contributor.author Crespo Barrio, Martaca
- dc.contributor.author Djamali, Arjangca
- dc.contributor.author Hertig, Alexandreca
- dc.contributor.author Öllinger, Robertca
- dc.contributor.author Portolés, Joséca
- dc.contributor.author Zuckermann, Andreasca
- dc.contributor.author Pascual Santos, Julioca
- dc.date.accessioned 2016-10-19T09:22:17Z
- dc.date.available 2016-10-19T09:22:17Z
- dc.date.issued 2016
- dc.description.abstract Steroid minimization after kidney transplantation has become more widely practiced as transplant clinicians seek the potential benefits such as reduced cardiovascular risk factors, improved growth in pediatric patients, and improved compliance with the immunosuppression regimen. Steroid avoidance (i.e. no steroids after the first week) is generally favored compared to later withdrawal. Induction therapy is routine in this setting, frequently rabbit antithymocyte globulin (rATG, Thymoglobulin®) or off-license use of alemtuzumab. Direct comparisons of steroid minimization regimens versus standard steroid regimens are rare. However, the available data show that the risk of acute rejection is low when rATG or alemtuzumab induction is given to support steroid-avoidance regimens after kidney transplantation. Steroid avoidance may be inadvisable in patients at high immunological risk or at risk of recurrent glomerular disease. Steroid withdrawal after day 8 may be possible without additional risk of rejection in patients iven rATG induction, but while encouraging, the data are too sparse for firm onclusions. In summary, steroid avoidance may be beneficial for patients after renal transplantation, with the potential to avoid or reduce steroid-related comorbidities. Whilst depleting induction therapy could be the treatment of choice, results of prospective randomized, controlled studies are eagerly awaitedca
- dc.description.sponsorship Julio Pascual and Marta Crespo are supported by grants FIS PI13/00598 and Redinren RD12/0021/0024.
- dc.format.mimetype application/pdfca
- dc.identifier.citation Naesens M, Berger S, Biancone L, Crespo M4, Djamali A, Hertig A. et al. Inducción con anticuerpos antilinfocitarios y minimización de esteroides en trasplante renal. Nefrologia. 2016 Sep - Oct;36(5):469-480. doi: 10.1016/j.nefro.2016.03.019ca
- dc.identifier.doi http://dx.doi.org/10.1016/j.nefro.2016.03.019
- dc.identifier.issn 0211-6995
- dc.identifier.uri http://hdl.handle.net/10230/27415
- dc.language.iso spaca
- dc.publisher Elsevierca
- dc.relation.ispartof Nefrologia. 2016 Sep - Oct;36(5):469-80
- dc.rights © 2016 Sociedad Española de Nefrología. Published by Elsevier España, S.L.U. This is/nan open Access article under the CC BY-NC-ND license/n ( http://creativecommons.org/licenses/by-nc-nd/4.0/).ca
- dc.rights.accessRights info:eu-repo/semantics/openAccessca
- dc.rights.uri https://creativecommons.org/licenses/by-nc-nd/4.0/ca
- dc.subject.other Ronyons -- Trasplantacióca
- dc.subject.other Esteroidesca
- dc.title Inducción con anticuerpos antilinfocitarios y minimización de esteroides en trasplante renalca
- dc.type info:eu-repo/semantics/articleca
- dc.type.version info:eu-repo/semantics/publishedVersionca